Sign in6 stories
The company said treatment began at Tel Aviv Sourasky Medical Center in a global study testing SIL204 alongside chemotherapy in locally advanced pancreatic cancer.
SEC filing
The company will lower the exercise price on existing warrants and issue new warrants to holders who agree to exercise, with closing expected September 29, 2026.
SEC filing
Silexion initiated its Phase 2/3 pancreatic cancer trial in Israel after German regulatory clearance, while cash fell to $2.2 million and it closed a $2.5 million offering.
SEC filing
The clinical-stage RNAi cancer company sold shares, pre-funded warrants and new warrants at $0.65, with proceeds earmarked for its SIL204 pancreatic cancer trial.
SEC filing (3)
The company disclosed in a July 31, 2026 filing that Professor Peled stepped down for personal reasons, effective August 1, 2026.
SEC filing
Tel Aviv Sourasky Medical Center becomes the first active site in Silexion's Phase 2/3 study of SIL204, with patient screening expected to start soon.
SEC filing